myRisk Gene TablePrint This Table
In addition to the 28 genes listed above, Myriad myRisk Hereditary Cancer includes riskScore, a precision medicine tool that predicts a woman’s five year and lifetime risk for developing breast cancer. riskScore analyzes over 80 genetic markers combined with the Tyrer-Cuzick model to estimate a woman’s risk for developing breast cancer.
riskScore is calculated for women under age 85, of solely European ancestry, without a personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results. riskScore is not calculated if the patient is known to carry a mutation in a breast cancer risk gene, or if there are any known mutations in the patient’s family.
To learn more about riskScore and the medical management guidelines provided for patients identified to have a remaining lifetime risk of breast cancer >20%, you may view the result insert by clicking the link below.
Genes selected for Myriad myRisk® satisfy these criteria:
- Cancer Focus
- Hereditable contribution
- Association with overlapping syndromes
- Cancer risk is at least 2-3 times the general population
- Clinically Significant
- Based on increased cancer risk from societal guidelines or determined by multiple studies
- Change in management inferred based on risk level
Each gene tested with Myriad myRisk links to one or more of eight cancer sites: Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, and Prostate.
Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk